期刊文献+

ACEI治疗中老年高血压的疗效观察与分析 被引量:6

ACEI for hypeitension in middle--aged and elderly patients
下载PDF
导出
摘要 目的探讨血管紧张素转换酶抑制剂(ACEI)类药物治疗中老年高血压的临床特点及疗效。方法将确诊为原发性高血压患者118例,观察患者使用ACEI类药物治疗前后的血压、肾脏功能、心功能、代谢功能变化情况。结果ACEI治疗后,患者收缩压和舒张压(P〈0.01),24小时尿蛋白定量(P〈0.05),左室舒张末容积和左室收缩末容积(P〈0.05和P〈0.01)明显降低,左室射血分数和心输出量明显增加(P〈0.05),差异有统计学意义。治疗前后患者的血钾、血肌酐、血糖、血脂无明显变化。结论ACEI在有效降血压的同时,保护心脏、肾脏功能,对糖、脂代谢无影响,是临床理想的降压药物。 Objective To explore the clinical efficacy of angiotensin-converting enzyme inhibitors (A- CEIs) for hypertension in middle-aged and elderly patients. Methods One hundred and eighteen patients with primary hypertension were treated with ACEI. Changes in blood pressure, renal function, cardiac function, and metabolic function were observed after treatment. Results Systolic and diastolic pressure (P〈0.01), 24-hour urinary protein (P〈0.05), left ventricular end-diastolic volume (P〈0.05), and left ventricular end-systolic vol- ume (P〈0.01) declined obviously, whereas left ventricular ejection fraction and cardiac output increased markedly (P〈0.05). All the differences were statistically significant. Meanwhile, no marked changes in serum potassium and creatinine and blood sugar and lipids were observed after treatment. Conclusions ACEIs effec- tively reduce blood pressure and protect cardiac and renal function, but have no effect on sugar and lipid metabolism. ACEIs are an ideal class of antihypertensive agents.
出处 《国际医药卫生导报》 2013年第1期68-71,共4页 International Medicine and Health Guidance News
关键词 高血压 ACEI 心功能 肾功能 Hypertension ACEIs Cardiac function Renal function
  • 相关文献

参考文献7

  • 1段秀芳,吴锡桂,顾东风,方渭清,黄广勇.中国人群血压分类与高血压患病率研究-1991年血压抽样调查资料的进一步分析[J].高血压杂志,2002,10(3):271-273. 被引量:67
  • 2顾东风,Jiang He,吴锡桂,Kristi Reynolds,甘文奇,刘东海,宿少勇,段秀芳,黄广勇,Paul K.Whelton.中国成年人高血压患病率、知晓率、治疗和控制状况[J].中华预防医学杂志,2003,37(2):84-89. 被引量:555
  • 3Whitworth JA,World Health Organization,International So-ciety of Hypertension Writing Group.2003 World Health Or-ganization (WHO)Antemational Society of Hypertension (ISH)statement on management of hypertension [J]J Hypertens,2003,21(11):1983-1992.
  • 4Patel BM, Mehta AA.Aldosterone and angiotensin : Role indiabetes and cardiovascular disease [J].Eur J Pharmacol,2012,697(1-3):1-12.
  • 5Mansia G,De Backer G,Dominiczak A,et al.2007 Guide-lines for management of arterial hypertension : the Task Forcefor the Management of Arterial Hypertension of the EuropeanSociety of Hypertension (ESH) and of the European Society ofCardiology(ESC)[J]. J Hypertens, 2007,25(6) : 1105-1187.
  • 6Vegter S, de Jong-van den Berg LT. Misdiagnosis and mis-treatment of a common side—effect—angiotensin—convertingenzyme inhibitor induced cough [J].Br J Clin Pharmacol,2010,69(2) :200-203.
  • 7Tardif JC,Curaew GP,Leclerc JM,et al.Reaching the thera-peutic goal in hypertension : results from the Canadian val-sartan observational study[J].Can J Clin Pharmacol,2008,15(2):el77-187.

二级参考文献13

  • 1全国血压抽样调查协作组.中国人群高血压患病率及其变化趋势[J].高血压杂志,1995,3(A01):7-13. 被引量:508
  • 2Lopez AD. Assessing the burden of mortality from cardiovascular diseases. World Health Stat Q,1993,46:91-96.
  • 3Murray CJ,Lopez AD. Global pattern of cause of death and burden of disease in 1990,with projections to 2020 investing in health research and development report of the ad hoc committee on health research relation to future intervention options. Geneva WHO,1996.
  • 4Wu Z,Yao C,Zhao D,et al. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China,Part I: morbidity and mortality monitoring. Circulation,2001,103:462-468.
  • 5Rodgers A,MacMahon S. Blood pressure and the global burden of cardiovascular disease. Clin Exp Hypertens,1999,21:543-552.
  • 6Klag MJ,Whelton PK,Randall BL,et al. Blood pressure and end-stage renal disease in men. N Engl J Med,1996,334:13-18.
  • 7Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure,cholesterol,and stroke in eastern Asia. Lancet,1998,352:1801-1807.
  • 8Tatsanavivat P,Klungboonkrong V,Chirawatkul A,et al. Prevalence of coronary heart disease and major cardiovascular risk factors in Thailand. Int J Epidemiol,1998,27:405-409.
  • 9Wolz M,Cutler J,Roccella EJ,et al. Statement from the National High Blood Pressure Education Program: prevalence of hypertension. Am J Hypertens,2000,13:103-104.
  • 10Primatesta P,Brookes M,Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension,2001,38: 827-832.

共引文献616

同被引文献48

  • 1黄丽娟,冯春玲,闫岩,姜秉荣.血管紧张素转换酶抑制剂的不良反应及处理[J].中国药业,2005,14(6):88-89. 被引量:2
  • 2吴波,何俐.钙通道阻滞剂预防脑卒中的临床证据[J].中国循证医学杂志,2005,5(10):792-796. 被引量:10
  • 3刘亚林,马景涛,孙芳毅,李星涛.高血压合并心力衰竭患者应用ACEI和ACEI联合ARB的随机对照研究[J].疑难病杂志,2006,5(6):427-430. 被引量:7
  • 4陈灏珠.实用内科学[M].11版.北京:人民卫生出版社,2003:5
  • 5Meghani SH, Becker D.Beta-hlockers: a new therapy in congestive heart failure[J].Am J Crit Care, 2001, 10(6): 417-427.
  • 6Brenner R, Rimoldi SF, Rexhaj E, et al. Arterial Hypertension- when are which combination therapies useful? [ J]. Ther Umsch, 2012,69(5) :305-313.
  • 7World Health Organization(WHO). World Health Statistics 2012. Geneva: WHO [ EB/OL ]. ( 2012-06-13 ) [ 2013-3-15 ]. http :// www. who. int/gho/publications/world _ health _ statistics/EN _ WHS2012_Full. pdf.
  • 8Fretheim A, Odgaard-Jensen J, Brcrs O, et al. Comparative effec- tiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis [ J]. BMC Med,2012,10( 1 ) :33-46.
  • 9Taddei S. Fixed-dose combination therapy in hypertension: pros [ J]. High Blood Press Cardiovasc Prev,2012,19 (2) :55-57.
  • 10Nieman LK, Biller BM, Findling JW ,et al. The diagnosis of Cush- ing's syndrome: an endocrine society clinical practice guideline [ J ]. J Clin Endocrinol Metab ,2008,93 ( 5 ) : 1526-1540.

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部